You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Rhinology

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

Prof. Peter Hellings highlights the EPOS/EUFOREA 2024 definition of remission and calls for an elevation of treatment goals in CRSwNP.

Peter Hellings
MD, PhD
Peter Hellings

Learning objectives

  • Evaluate recently published definitions of remission in CRSwNP with an eye toward improving patient outcomes

Description

Prof. Peter Hellings highlights the EPOS/EUFOREA 2024 definition of remission and calls for an elevation of treatment goals in CRSwNP.

Tags
expert insightsstandard of caredisease controlguidelinesremission
MAT-GLB-2401111 - 1.0 - 04/2024

About this expert

Rhinology

Peter Hellings

MD, PhD

Professor and Clinic Head of the Department of Otorhinolaryngology | University Hospitals of Leuven, Belgium

See author’s profile
Peter Hellings

Related resources

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation
Rhinology
expert video

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

ADVENT On Air | Loss of Smell in CRSwNP Patients
Rhinology
Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Remission in CRSwNP
Rhinology
Podcast

ADVENT On Air | Remission in CRSwNP

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Pulmonology
expert video

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

Connecting Type 2 Inflammation to CRSwNP
Rhinology
expert video

Connecting Type 2 Inflammation to CRSwNP

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients
Rhinology
interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission
Rhinology
expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

CRSwNP: A Chronic Type 2 Inflammatory Disease
Rhinology
expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

Partnering With Patients: Scores That Matter in CRSwNP
Rhinology
interactivity

Partnering With Patients: Scores That Matter in CRSwNP

Loss of Smell is a Key Symptom of CRSwNP
Rhinology
Infographic

Loss of Smell is a Key Symptom of CRSwNP

What proportion of patients can achieve control in CRSwNP?
Rhinology
expert video

What proportion of patients can achieve control in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Rhinology
expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?
Rhinology
expert video

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

When is the right time to consider a biologic in patients with CRSwNP?
Rhinology
expert video

When is the right time to consider a biologic in patients with CRSwNP?

How often do you suggest to assess sense of smell?
Rhinology
expert video

How often do you suggest to assess sense of smell?

How does a decrease in smell affect sleep disturbance? Is there any direct relation?
Rhinology
expert video

How does a decrease in smell affect sleep disturbance? Is there any direct relation?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Rhinology
expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Rhinology
expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Pulmonology
expert video

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region